The Current Place of Progestins in the Treatment of Endometriosis

Karl-Werner Schweppe


Expert Rev of Obstet Gynecol. 2012;7(2):141-148. 

In This Article

Five-year View

This review has demonstrated the lack of sufficient prospective randomized trials comparing different progestins and different dosages, which is a need for the future. The new drugs under development for the medical treatment of endometriosis are targeting different steps in the pathogenesis – for example, inhibitors of vascular epithelial growth factors, matrix metalloproteinase inhibitors or immunomodulatory substances like TNF-α inhibitors. First results in laboratory or animal studies are promising, but their use in humans is far from being achieved. Therefore, for the next 5–10 years, progestins alone or in combination with pain-relieving strategies are very important drugs for the medical treatment of endometriosis in general, whereas GnRH analogs still have their place in special indications.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: